TREATMENT DECISIONS ACCORDING TO 1-YEAR RISK MORTALITY IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY.

AUTHORS: H. RODRIGUEZ-RAMALLO1, N. BÁEZ GUTIÉRREZ2, B. APARICIO CASTELLANO2, A. RODRÍGUEZ PÉREZ1, B. SANTOS RAMOS1, L. RODRÍGUEZ DEFRANCISCO1, M. FERNÁNDEZ GONZÁLEZ1.

1- HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, PHARMACY, SEVILLE, SPAIN.
2- HOSPITAL REINA SOFIA, PHARMACY, CÓRDOBA, SPAIN.

Background and importance

The 2015 and 2022 ESC/ERS Guidelines for pulmonary hypertension treatment provide algorithms for decision-making based on patients' 1-year mortality risk, with strong recommendations to intensify treatment in patients with intermediate-high risk.

Aim and objectives

To assess whether treatment decisions in pulmonary arterial hypertension [PAH] patients are currently being made according to the treatment algorithms provided by the ESC/ERS Guidelines.

Material and methods

✓ Study design: retrospective, descriptive, cross-sectional
✓ Setting: two tertiary hospital.
✓ Study period: March 2022
✓ Variable collected: demographics, PAH subclassification according to aetiology, PH-specific drug initiated, World Health Organisation functional class [WHO-FC], 6-minute walking distance [6MWD], and N-terminal pro-brain natriuretic peptide [NT-proBNP].
✓ Assessment: 2022 ESC/ERS Guidelines algorithms.

Results

Material and methods

Poster number

6ER-012

54.1% 45.9%

50 (28-84) years

37 compiled inclusion criteria

52 changes in pulmonary-specific therapy

36 treatment initiations according to clinical guideline algorithms

1-year risk mortality

Low Intermediate-low Intermediate-high High

27% 2% 38% 33%

most discrepancies
• Selexipag (n=9)
• Riociguat (n=3)
in patients with risk other than intermediate-low.

Conclusion and relevance

In this cohort of PAH patients whose 1-year mortality risk could be estimated, treatment decisions were generally made according to treatment guidelines. Patients' preferences could explain most discrepancies, as they may prioritise avoiding treatments that require parenteral administration, such as epoprostenol and treprostinil and rather try oral alternatives.

Poster number

6ER-012

54.1% 45.9%

50 (28-84) years

37 compiled inclusion criteria

52 changes in pulmonary-specific therapy

36 treatment initiations according to clinical guideline algorithms

1-year risk mortality

Low Intermediate-low Intermediate-high High

27% 2% 38% 33%

most discrepancies
• Selexipag (n=9)
• Riociguat (n=3)
in patients with risk other than intermediate-low.

Conclusion and relevance

In this cohort of PAH patients whose 1-year mortality risk could be estimated, treatment decisions were generally made according to treatment guidelines. Patients' preferences could explain most discrepancies, as they may prioritise avoiding treatments that require parenteral administration, such as epoprostenol and treprostinil and rather try oral alternatives.